Concordance between EMA Good Clinical Practice inspections and medical literature concerning drugs that have not received marketing authorization in the European Union: a meta-research survey
Terre, A.; Becker, O.; Ioannidis, J.; Naudet, F.
Show abstract
ObjectivesTo describe the differences between European Medicine Agency (EMA) Good Clinical Practice (GCP) inspection reports and medical literature on drugs with withdrawn or refused applications. DesignA retrospective study comparing studies included in European Public Assessment Reports (EPARs) and the corresponding articles published in the medical literature. Data sourcesWe screened all EPARs released by the EMA from inception to April 2024 for drugs that were refused or had a withdrawn application. In those EPARs, we looked for mentions of GCP inspections and details about them, then we searched for related publications on the inspected studies on bibliographic databases. Eligibility criteriaAll EPARs mentioning good clinical practice inspection were included in this survey. Data extractedTwo reviewers independently gathered information on the GCP inspections and their findings, including the EMAs opinion on their impact on the study data. The reviewers checked related publications for mentions of the inspection and any subsequent correction, retraction, or expressions of concern related to its findings. Main outcome measuresThe main outcome was the mention of the GCP inspection findings in the publication of the inspected studies. We also assessed whether there was any mention of these findings in a correction, retraction, or expression of concern. ResultsOut of 285 EPARs screened, 57 (20%) mentioned a GCP inspection. 58 distinct studies with inspections had 61 publications. For 17 publications the inspection occurred after the publication, for 20 the inspection happened before the publication, and for 24 the date of the inspection was unknown. Only 1 publication (2%) addressed the inspection findings. Moreover, there were no corrections, retractions, or expressions of concern related to inspection findings. Among the 61 publications, 26 (43%) were related with 24 distinct studies that had an inspection that casted doubts on data reliability, but none mentioned the inspections at or after the time of publication. ConclusionsThis meta-research survey indicates that health authorities GCP inspections are not reflected in the published literature, even when the inspections have put the data reliability in doubt. Journals should clearly specify which aspects of those studies are trustworthy and which ones are not. Trial registrationosf.io/pa9fq/
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 95%
- Preventable deaths involving medicines in England and Wales, 2013-22: a systematic case series of coroners’ reports 93%
- Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies 93%
Similar papers in this journal
- Application of observational research methods to real-world studies for rare disease drugs: a scoping review protocol 95%
- COVID-19-related research data availability and quality according to the FAIR principles: A meta-research study 94%
- Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trials 94%
Similar papers in this journal
- Reporting of Retrospective Registration in Clinical Trial Publications 97%
- Comparison of preprints and final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in interpretation 96%
- An Analysis of Controlled Human Infection Studies Registered on ClinicalTrials.gov 95%
Similar papers in this journal
- Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed 96%
- The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study 96%
- Results dissemination from clinical trials conducted at German university medical centres was delayed and incomplete 95%
Similar papers in this journal
- Semantic and geographical analysis of Covid-19 trials reveals a fragmented clinical research landscape likely to impair informativeness. 92%
- Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial 91%
- Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.